MGB Biopharma to Attend Upcoming BioEurope Meeting in Hamburg on 11 to 13 Nov 2019

October 29, 2019

Glasgow, Scotland, 29^th October 2019 – Dr Miroslav Ravic and Chris Wardhaugh from MGB Biopharma will be meeting with partners at BioEurope 2019 in Hamburg to discuss the latest data from the company’s clinical study. Should you wish to schedule a meeting please do so through the partnering software, or alternatively contact Chris Wardhaugh at cwardhaugh@mgb-biopharma.

News

MGB Biopharma Announces Successful End-of-Phase 2 Meeting with FDA for MGB-BP-3, a Potential New Gold Standard, First-Line Treatment for Clostridioides difficile Infection (CDI)

MGB Biopharma Announces Successful Outcome from Phase II Clinical Study with MGB-BP-3 – a Potential New Gold Standard, First-Line Treatment for Clostridium difficile Infection (CDI)

MGB Biopharma to Attend Upcoming BioEurope Meeting in Hamburg on 11 to 13 Nov 2019

News & Events

News

MGB Biopharma Announces Successful End-of-Phase 2 Meeting with FDA for MGB-BP-3, a Potential New Gold Standard, First-Line Treatment for Clostridioides difficile Infection (CDI)

MGB Biopharma Announces Successful Outcome from Phase II Clinical Study with MGB-BP-3 – a Potential New Gold Standard, First-Line Treatment for Clostridium difficile Infection (CDI)

MGB Biopharma Presents at INV€$TIVAL SHOWCASE 2019

MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3

MGB Biopharma Announces Completion of Funding Round

Join our mailing list